{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:42Z","timestamp":1740144042593,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40256-020-00398-x","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T03:02:40Z","timestamp":1581390160000},"page":"611-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease"],"prefix":"10.1007","volume":"20","author":[{"given":"Meredith L.","family":"Hampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-9888","authenticated-orcid":false,"given":"Katie B.","family":"Tellor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-4118","authenticated-orcid":false,"given":"Anastasia L.","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gus","family":"Theodos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin W.","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIR.0000000000000645","volume":"139","author":"T January","year":"2019","unstructured":"January T, Wann L, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;139:1\u201349.","journal-title":"Circulation."},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:160S\u201398S.","journal-title":"Chest."},{"key":"398_CR3","unstructured":"Eliquis (apixaban) [prescribing information]. Princeton: Bristol-Myers Squibb; 2019. Available online from https:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed 8 Feb 2020."},{"key":"398_CR4","unstructured":"Savaysa (edoxaban) [prescribing information]. Parsippany: Daiichi Sankyo; 2019. Available online from https:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true. Accessed 8 Feb 2020."},{"key":"398_CR5","unstructured":"Pradaxa (dabigatran) [prescribing information. Ridegefield: Boeringer Ingelheim Pharmaceuticals Inc; 2019. Available online from https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf. Accessed 8 Feb 2020."},{"key":"398_CR6","unstructured":"Xarelto (rivaroxaban) [prescribing information]. Titusville; Janssen Pharmaceuticals Inc; 2019. Available online from http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf. Accessed 8 Feb 2020."},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N\u20139N.","journal-title":"Am J Cardiol."},{"key":"398_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke."},{"key":"398_CR9","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","volume":"6","author":"K Pan","year":"2017","unstructured":"Pan K, Singer D, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835.","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"398_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost."},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"G Lip","year":"2010","unstructured":"Lip G, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest."},{"key":"398_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the euro heart survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest."},{"key":"398_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"C Granger","year":"2011","unstructured":"Granger C, Alexander J, McMurray J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med."},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"R Giugliano","year":"2013","unstructured":"Giugliano R, Ruff C, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med."},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"S Connolly","year":"2009","unstructured":"Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med."},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"M Patel","year":"2011","unstructured":"Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med."},{"key":"398_CR17","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"G Lip","year":"2018","unstructured":"Lip G, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49:2933\u201344.","journal-title":"Stroke."},{"issue":"12","key":"398_CR18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaneurol.2018.2215","volume":"75","author":"W Huang","year":"2018","unstructured":"Huang W, Singer D, Wu Y, et al. Association of intracranial hemorrhage risk with non-vitamin K antagonist oral anticoagulant use vs aspirin use. JAMA Neurol. 2018;75(12):1511\u20138.","journal-title":"JAMA Neurol."},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","volume":"184","author":"S Windecker","year":"2017","unstructured":"Windecker S, Tijssen J, Giustino G, et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J. 2017;184:81\u20137.","journal-title":"Am Heart J."},{"key":"398_CR20","unstructured":"Cooper TP. Rivaroxaban (Xarelto): Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial (Dear Healthcare Professional letter dated October 3, 2018). Available online from http:\/\/www.hpra.ie\/docs\/default-source\/default-document-library\/important-safety-information---xarelto-(rivaroxaban)-(oct-2018).pdf?sfvrsn=0. Accessed 8 Feb 2020."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-020-00398-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T06:18:12Z","timestamp":1665814692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-020-00398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00398-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"11 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Schwarze is on the speaker\u2019s bureau for Pfizer\/BMS. Dr. Hampton, Dr. Tellor, Dr. Armbruster, and Dr. Theodos have no potential conflicts of interest that might be relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}